Stages:
Min Investment:
Max Investment:
Target Investment:
Total Funding: $52M
Total Funding: $90M
Total Funding: $60M
Total Funding: $75M
Total Funding: $75M
Total Funding: $40M
Total Funding: $50M
Total Funding: $50M
2024
2019 - 2024
Apple Tree Partner's (ATP’s) unique model follows the science, brings together the best teams, and deploys significant capital to create and build the next generation of innovative biotechnology companies.
2023
Lead all activities at a research stage biotechnology company focused on designer synthetic RNA therapeutics and RNA exon editing. Deploying innovative technology platforms to create breakthrough therapies for debilitating ophthalmological, neurological, neuromuscular, and rare diseases.
2022 - 2023
Scientific and corporate leadership of research stage biotechnology company developing designer synthetic RNA therapeutics and RNA exon editing therapies for ophthalmological, neurological, neuromuscular, and rare diseases.
2020 - 2022
Lead all activities at a research stage biotechnology company focused on designer synthetic RNA therapeutics and RNA exon editing. Deploying innovative technology platforms to create breakthrough therapies for debilitating ophthalmological, neurological, neuromuscular, and rare diseases.
2021
Scientific and corporate leadership of research stage biotechnology company developing novel self-replicating RNA therapies for cancer, autoimmune disorders, and infectious diseases.
2020
2020
Scientific and corporate leadership of research stage biotechnology company developing novel immunotherapies for the treatment of diverse cancers.
2020 - 2023
2023 - 2023
Scientific and corporate leadership of research stage biotechnology company developing non-viral gene therapies for ophthalmological diseases.
2020 - 2023
Led all activities at a cutting-edge start-up biotechnology company focused on non-viral gene therapy. Deploying molecular biology and bioengineering platforms to create breakthrough therapies in ophthalmology.
2019 - 2020
2019 - 2020
Led a cutting-edge start-up biotech company focused on gene therapy and genetic medicines for patients with severe inherited diseases.
2016 - 2019
2016 - 2019
led global R&D for a cutting edge, industry-leading biotechnology company
2010 - 2016
2015 - 2016
Lead R&D activites in a large division of a leading biopharmaceutical company.
2010 - 2016
lead global research and development in neuroscience to create innovative medicines that effectively treat brain disorders
2010 - 2011
2010 - 2011
2005 - 2010
2005 - 2010
1998 - 2010
1998 - 2010